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‘Tim ‘l’ull\- and Jerry Yin have matic 
flits \l.irh photographic mcmorics, 
and vith the backing of a major 
pharmaceu&al company they hope 
to transfer some of that capability to 
humans. M.hcther or not thy are the 
first fn succeed. it seems almost 
inevitable that society will soon fact 
the question of lvhechcr more - bc 
it hair (Propccia), weighr-loss (Fen- 
phcn). sex (\bgra), or now memories 
- is al~3~s betccr. 
Building a better fly 
Ilelicon ‘I’hcraj~cutics. Inc. is a 
collaborative \‘cncurc between ‘I’ully 
and Yin (Cold Spring Harbor 
I ,aborator?, Cold Spring Harbor. Sew 
York). OS1 Pharmaceuticals. Inc. 
(Uniondalc. Sew li)rk) and Kochc 
I Iolding Ltd. (Rasel. Switzerland). 
“lc’s cssentiall>- a Iirtllal comj’an);” 
say CEO \\lter Lovcnbcrg. 
Its focus is the cAJIP-rcsponsivc 
clement-binding protein (CRE:B): its 
inspiration is the I\-ork of Seymour 
Bcnzcr and the isolarion ofn’wru, the 
original I)lns0phih melmmgusftlr 
Icarning mutant. L)z/uc which 
encodes a cX.\IP phosphodiesterase, 
and irs sllccessor rxf+y, a 
calciilm/calmod~rlin-depcndcndct 
adenyl c)-clasc, led 10 CRE I%. 
Riot Tully and Yin’s first task was 
to dcfinc fly memory stages. They 
cxposcd flies to one odor \j.hilc they 
were given rcpcated shocks. and 
another odor in the ahsencc of 
shocks. ‘liaincd flits were then 
asked to choose bctwccn the two 
odors in ii simj)lc ‘I‘-maze. 
.~ .~ 
‘Italicized quotations are from “Flowers for 
Algernon” :t‘ 1966 Daniel Keyes (renewed 
1994), published by Harcourt Brace & Co. 
~1 single training session resulted 
in a low Ic14 of short-lived memory 
‘I’en consecutive training sessions 
improved chc memory somewhat. 
but it was still short-lived. Only with 
ten spaced training sessions did the 
flits retain their lesson for o\‘cr seven 
days, a long time for a fly 
It was with CREB that ‘li~lly and 
I’in hit the jackpot. In exj>erimcnts 
j’ublishcd in 1994 and 199.5. they first 
knocked out fly long-term memory by 
expressing a repressor fonn of CREB. 
and then created photograj)hic 
memory - long-term memories after 
only a single training session -by 
cxjjressing an activaror form of CKEH. 
‘I‘his was not just a 11) 
phenomenon. Eric Kandcl (Colllmbia 
I!nivcrsity. hew \rbrk) had reduced 
the gill withdrd\vdl reflex of rhc sea 
slug .4p(kz to a cellular model 
involving onlv 3 single sensor\ 
neuron and a single motor neuron. 
Seroronin. normally supplied by an 
intcrneuron. could mimic the effect 
of training. which strengthens the 
synapse and thercforc enhances the 
next response of the gill to a noxious 
chemical. Cyclic A\lP and (XEB 
wcrc implicated in this process. 
Knockouts in mice. although 
imperfect bccausc of multiple gents 
and splice forms, strongly sllggcsted 
that \.arious forms of memory in mice 
necdcd CRER. This n-as contirmcd in 
rats using antisensc oligonllclcotides. 
‘I’he cllrrent model for long-term 
memory in flies involves a calcillm 
influx acrivating Rutabaga jXotein 10 
produce c,Ulf! which frees j)rolein 
kinase A from its inhibitor so it can 
phosphorylate CREB. I’hosphorylated 
CRF,R binds to (:REU-dcpcndcnt 
genes. and the products of thcsc gcncs 
ultimately change syaptic structure. 
The first step 
Prof Nemur says //it werks good and ifs 
perminenf they w//l make other pep/ like me 
smart also. Maybe pepul all over the werld. * 
‘I’hc first field of attack for memory- 
enhancing drugs is Alzhcimer’s 
discasc. The apj)rovcd drugs include 
the acctvicholincsterase inhibitors 
Cogncx (tacrinc hyirochloridc: 
Parke-Davis). Aricepr (doncrepil; 
Eisai Company and I’fizcr) and 
Exclon (ENA-71.3: Swlartis: 
approved only in Elmye). ‘I’hesc 
drugs have limited efficacy. aI best 
effecting onI\: a short-lived increase 
in acec)-Icholine-teased transmission. 
The aj)j)roach of Cortex 
I’harmaccllticals. Inc. (Irvine. 
Mifornia) is more closely tied to 
mechanisms of memory formation. 
Hased on the work of Gary I,ynch 
(I’ni\lersit)i of California, Iwine). 
Cortex is targeting chc iI.\IPA 
receptor, one of many Ir;lutamnte 
rcccptors. ‘I‘he :Wf’.-\ rcccptor is 
in\.olvcd in long-term potcntiation 
(LTP). the long-term strcngthcning 
of synaj~~s thar is thought to bc 
involved in vcrtcbratc learning and 
memory LIcpolarization of the 
membrane by the .NPA rcccptor 
ojjens the NhIDj\ rcccptor. \vhich 
allow calcium entry and I;l’P. 
‘I’hc first of Cortex’s ‘ampakincs’ 
is in phase I/Jla trials for ;Ilzheimer’s 
and schizophrenia. 1,) nch claims that 
drug spcciiicity should he good. “On 
its own [the drug] doesn’t crcatc 
ncurotransmission.” he says. “WC 
increase synaptic transmission, bur 
only where it normally occurs.” ;Is a 
rcsulc thcrc appears to be little if an); 
cffcct on the disposition of the trial 
particij>ants. “‘l‘hey don’t feel a bllzz; 
they don’t feel activated.” says L);nch. 
Early results look jwomising. 
according to I.,):nch. “Thcrc seems co 
bc a small cffcct in young people,” 
hc says. “Rut tvhen you ha1.e a 
deficit the drug is more effccti\:c.” 
The Helicon approach 
For ;I company formed in 1907. 
I Iclicon has not been wasting time. 
OSI has used cell lines with (XEB 
promoters linked to luciferasc 
rcportcrs to test R&e’s collection of 
-200.000 nellro-biased chemicals for 
inducrion of CREB activator function. 
I,ovenberg reports thar thcrc has been 
a hcalrhy hit rate. The best lcads will 
bc tcstcd in flies and mice at Cold 
Spring Harbor, using a Wchambcr 
automated system for rhc flies. 
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h,leanwhile. Kandel has reccntl\: 
formed .\lemor) Pharmaceilticals to 
exploit his CREB-r&ted work. j\t 
press time the company spokesperson, 
CEO Axcl I:nterbcck, \vas refusing 
interviews from both C:/I~wzSfq @ 
Hiolo~ and the T\’ ne\I.smagazinc 
X/20, citing lack of time. 
Thus is-seems likely that a CREB 
acti\.ating drug will be found. The 
next question is what it \\.ill do. 
There arc many forms of long-win 
memory, depending on the learning 
paradigm. hiark \~lal;ford (L’nivcrsity 
of California, San Diego) does not 
see this as a problem. “It’s really at 
the anatomical level that thcsc 
distinctions occur,” hc says. “By 
tapping into this molecular pathway 
you should tap into almost all forms 
of Icarning.” 
(.:RI’B has its detractors. houzvcr. 
“‘l‘hc very fact that they call CRER 
the master w.itch should be CIIISC for 
concern.” says I,ynch. Contrasting 
CREB to the ampakine approach of 
only increasing existing acti\it); he 
says: “It ma! do things ~OII don’t want 
done.” CREH is also involl:cd in a 
host of signal-transduction events 
outside the brain. Hclicon is therefore 
investigating DNA chip technologies 
to find targets of (;KT:R transcriptional 
acti\Xion that arc inlA\.cd 
specifically in mcmor): formation. 
Why do we need a smart drug? 
If your smart you can Aave /ots of fiends to 
la/k to and you ne~vzr get lo&y by yourself 
all fhe f/me. 
AlAcirner’s is a common excuse for 
memory drug dc\:elopmcnt, blrt that 
idea is not without its flaws - 
:\lzheimcr’s is a disease of ncr\le 
degeneration. not defcctile CREB 
functioning. “Our rationale is that a 
drug that would cnhancc memop 
might enhance the functioning of the 
neurons that are sur\4\ing,,” say 
1,ovenberg. “Clearly it will not bc a 
curati\-e trcatmcnt, but hopefully the 
neurons that remain will work 
better.” Ma)-ford calls this “unlikely.” 
But :1lzheimcr’s is far from the 
only mcmor); disorder. and James 
~1cGaugh of the I-nivcrsity of 
Glifornia. Irvine, would welcome 
therapies for other indications. 
“‘l’hesc diseases arc devastating,” he 
says. “You lost who you are - ):OII 
arc your mcmorics. It \vould bc a 
blessing to ha\.e [memory] drugs.” 
‘I‘hc ultimate back-up plan 
invol\zs the largest potential market: 
cveryonc. “You woi~ld only get [a 
memory drug) approlwl for 
marketing for a defined clinical 
indication - you wouldn’t get it 
appro\& for kids taking tests.” says 
Lovenbcrg. “On the other hand. 
there are ii wide I-aricty of situation5 
where a mcmor): drug could he Iwd. 
The defense departlnent appears to 
bc intercstcd in this approach. Being 
able to train the military over a vcr! 
short period of time before a mission 
would bc of great interest to them.” 
‘I‘he in& interest lies in 
reversing age-related memory loss: in 
short, solving the ‘v.hcrc are m): 
keys?’ problem. “Sot much is known 
abollt what underlies these changes. 
l’he major change is sludginess - 
things just get slower,” say 
.\,lcGaugh. “Xnything that impro\.es 
the strength of memory lvill improvc 
the speed of recall.” It seems likeI> 
that only memory of what occurred 
while the subject was taking the 
drugs will bc improved. 
Few anticipacc that any decent 
memory drug Lvill be controlled by 
anyone. including the I.;S Food md 
Drug :L\dministration (1:D.A). “Gi\.en 
the situation in the I.[!2 whcrc 
physicians cannot be controlled and 
the elderly population is cager to 
impro1.e their condition of health. I 
think there will be pressure [to 
prescribe off-indication].” says 
Cortex’s I,ynch. According to 
\lcGaugh. “‘l‘his could bc the \‘iapra 
for intcllcctual fiinctioning.” 
Complications 
“The more infelligenf you become fhe more 
problems you’ll have, Charlte.* 
“It’s a classical double-edged s\vord. 
[;I memory drug is] needed \er) 
bad]!. but it’s open to abuse.” says 
\lcGaugh. “If someone takes it 
hcfore an entrance exam, could a 
medical school make it a condition of 
entry that the)- keep taking it? Or 
could the medical school sue for 
fraud? YOLI can imagine that an 
cmploycr \vo~~ld make a condition of 
cmploymcnt that you use these 
drugs.” 
AlcGaugh says some of these 
concerns are not new. “Valium is the 
most \ridcly prcscribcd drug for 
anxiety disorders, hut do yoii need it 
because you arc a littlc nervous 
about giving a speech? ?‘his is drug 
abuse in the social sense.” 
Of course, there is al\vays the 
possibilit!; that a memory drug will 
backfire. “‘l-his ma); help ):ou form 
associations better, but if you do that 
for a long enough period ):OLI might 
run into problems.” says hlayford. 
“Once there’s too much information 
\-ou ma): slow things dow:n. 50 that 
something that took ten seconds now 
takes half an hour.” 
‘I‘hen there is the problem of 
1% hethcr superior memory equals 
intelligence. which may bc \vhat the 
general public is really after. Obser\lcs 
Lovenbcrg: “From casual observation. 
I have known several indi\:iduals with 
basically photographic mcmor);. 1 
\+..cnt to graduate school with a 
student iike this. I thought. ‘This 
person will knock the \\orld dead.’ 
But he was a total failure in research. 
Perhaps hc wasn’t creative enough, or 
he had his brain clllttcred with too 
man): things.” 
“If y011 instill4 in soniebod~ the 
capacity to remcmbcr everything 
they heard and saw they might ha\:e 
defects in their ability to reason or 
recall.” say Lolenberg. “I am sure 
\:OII could ha\-e too much of a good 
thing. Rut in man): situations, 
impro\.ing the storugc in long-term 
memory, if it’s not &rdonc,-could 
be \.cry positi1.e.” 
Whaf’s righf? ironic fhaf all my infelligence 
doesn’t he/p me so/w a problem lke this. 
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